SavedAdd your journal

Journals / Klinik Tıp Bilimleri / 2017 / Cilt: 5 - Sayı: 4

Current Pharmacological Treatment Algorithmin Type 2 Diabetes

Tip 2 Diyabette Güncel FarmakolojikTedavi Algoritması

Dr. Özge POLAT KORKMAZ
Pages
71–75
Publication Date
2017-04-10
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

For patients with type 2 diabetes who are not achieving glycemic goals, insulin therapy should not be delayed..

📌 3 Key Takeaways

🎯
Objective & Hypothesis:AbstractA patient-centered approach should be used to guide the choice of pharmacologic agentsand for glycemic goal in Type 2 DM.
📊
Key Findings & Data:Considerations include efficacy, hypoglycemiarisk, impact on weight, potential side effects, cost and patient preferences.
💡
Conclusion & Impact:For patients with type 2 diabetes who are not achieving glycemic goals, insulin therapy should not be delayed..
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Tip 2 DM · tedavi · Type 2 DM

Abstract

AbstractA patient-centered approach should be used to guide the choice of pharmacologic agentsand for glycemic goal in Type 2 DM. Considerations include efficacy, hypoglycemiarisk, impact on weight, potential side effects, cost and patient preferences. Lifestyle modifications that improve health care should be emphasized along with any pharmacologic therapy. For patients with type 2 diabetes who are not achieving glycemic goals, insulin therapy should not be delayed..

Özet

ÖzTip 2 DM tedavisinde güncel yaklaşım; glisemik kontrol hedeflerinin ve kullanılacak farmakolojik ajanların seçiminin hasta merkezli olması yönündedir. Bununla birlikte seçilecek ilacın etkinliği, hipoglisemi riski, kilo üzerine etkisi, muhtemel yan etkileri, maliyet ve hasta tercihleri de tedavi planında dikkate alınmalıdır. Yaşam tarzı değişiklikleri,uygulanacak farmakolojik tedavi ne olursa olsun tedaviye eklenmelidir. Glisemik hedeflere ulaşılamayan tip 2 diyabet hastalarında insülin tedavisi geciktirilmemelidir.

🔖

Cite This Article

KORKMAZ, D. Ö. P. (2017). Current Pharmacological Treatment Algorithmin Type 2 Diabetes. Klinik Tıp Bilimleri, Cilt: 5 - Sayı: 4, 71–75. https://ajindex.com/articles/838271

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (11)

  1. Kaynaklar 1.Cornell S. Comparison of the diabetes guidelines from the ADA/EASDand the AACE/ACE J Am Pharm Assoc (2003). 2017
  2. 57(2):261-265. 2.Marathe, P.H., et al,American Diabetes Association Standards of Me-dical Care in Diabetes 2017. Diabetes Care 2017,40(Suppl. 1):66 3.Rodbard HW, Jellinger PS, Davidson JA, Einhorn D, et al. Statementby American Association of Clinical Endocrinologists/ American Col-lege of Endocrinology Consensus Panel on Type 2 Diabetes Mellitus:An algorithm for glycemic control. Endocr Pract 2009
  3. Canadian Diabetes Association. 2008 Clinical Practice Guidelinesfor the Prevention and Management of Diabetes in Canada. Cana-dian J Diabetes 2008
  4. 32(Suppl. 1):1-215. 5.National Institute for Health and Clinical Excellence (NICE). Type 2diabetes: the management of type 2 diabetes. 2008. (www.nice. org.uk). 6.Nathan DM, Buse JB, Davidson MB, et al. Medical management ofhyperglycemia in type 2 diabetes -a consensus algorithm for the ini-tiation and adjustment of therapy: a consensus statement of the Ame-rican Diabetes Association and the European Association for the Studyof Diabetes. Diabetes Care 2009
  5. 193–203. 7.Diabetes Mellitus ve Komplikasyonlarının Tanı,Tedavi ve İzlem Kı-lavuzu-2016 8.Palmer SC, Mavridis D, Nicolucci A, et al. Comparison of clinicaloutcomes and adverse events associated with glucose-lowering drugsin patients with type 2 diabetes: a meta-analysis. JAMA2016
  6. 313–324 9. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HAW. 10-yearfollow-up of intensive glucose control in type 2 diabetes.N Engl J Med2008
  7. 1577–1589 10. Bennett WL, Maruthur NM, Singh S, et al. Comparative effectivenessand safety of medications for type 2 diabetes: an update includingnew drugs and 2-drug combinations. Ann Intern Med2011
  8. 602–613 11. Aroda VR, Edelstein SL, Goldberg RB, et al.
  9. Diabetes PreventionProgram Research Group.Long-term metformin use and vitamin B12defi- ciency in the Diabetes Prevention Program Outcomes Study.J Clin Endocrinol Metab 2016
  10. 1754–1761 12. Inzucchi SE, Bergenstal RM, Buse JB, et al. Management ofhyperglycemia in type 2 diabetes, 2015: a patient-centered appro-ach: update to a position statement of the American Diabetes Asso-ciation and the European Association for the Study of Diabetes. Dia-betes Care 2015
  11. 140–149 13. Chiasson J-L, Josse RG, Hunt JA, et al.The efficacy of acarbose inthe treatment of patients with non-insulin-dependent diabetes mel-litus. A multicenter controlled clinical